<DOC>
	<DOCNO>NCT01845740</DOCNO>
	<brief_summary>Milatuzumab give subcutaneously different dose level ( depend dose level ) 4 week determine milatuzumab help control lupus ( SLE ) .</brief_summary>
	<brief_title>Phase Ib Study SC Milatuzumab SLE</brief_title>
	<detailed_description>Milatuzumab placebo give subcutaneously weekly 4 week determine milatuzumab help control lupus ( SLE ) . The treatment portion study last 4 week . Then patient follow disease activity least 12 week . If patient respond study drug , may eligible one course retreatment , follow 12 week follow-up . Patients show response continue follow timepoints one year treatment ass long response last .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Lupus Erythematosus , Discoid</mesh_term>
	<mesh_term>Vasculitis , Central Nervous System</mesh_term>
	<mesh_term>Lupus Vasculitis , Central Nervous System</mesh_term>
	<criteria>Male female ≥ 18 year old Signed write informed consent study entry Diagnosis SLE American College Rheumatology revise criterion ( meet ≥ 4 criterion ) Positive ANA ( titer ≥ 1:80 ) study entry At least 1 BILAG A 2 BILAG B score organ/body system ≥ 6 SELENASLEDAI score Receiving least 5.0 mg/day oral prednisone ( equivalent ) stable dos least 4 week prior study entry If receive immunosuppressive antimalarial agent , stable dos least 4 week prior study entry Pregnant lactate woman . Women childbearing potential must negative pregnancy test . Women childbearing potential fertile men practice unwilling practice birth control study Rituximab , belimumab , prior antibody , investigational experimental therapy within 6 month Allergic murine , chimeric , humanize human antibody Hematologic abnormality attribute lupus : hemoglobin &lt; 8.0 mg/dL , WBC &lt; 2000/L , ANC &lt; 1500/L , platelet &lt; 50,000/L , AST , ALT alkaline phosphatase &gt; 3 time upper limit normal attribute lupus Serum creatinine &gt; 2.5 mg/dL , proteinuria &gt; 3.5 g/day Received live vaccine within 4 week Thrombosis , spontaneous induced abortion , stillbirth live birth within 4 week Antiphospholipid antibody AND history thromboembolic event On oral anticoagulant ( include NSAIDs ) within 4 week Active infection antibiotic within 7 day Infection require hospitalization herpes zoster treatment within 4 week Longterm infectious disease ( tuberculosis , fungal infection ) active within 2 year Malignancy ( except squamous basal cell carcinoma , cervical CIS ) within 3 year ( unless approve medical monitor ) History recurrent abortion ( 2 ) Known HIV , hepatitis B C , immunosuppressive state Other concurrent medical condition , investigator 's opinion , could affect patient 's ability tolerate complete study eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>systemic lupus erythematoses</keyword>
	<keyword>lupus</keyword>
	<keyword>SLE</keyword>
</DOC>